

Global Amyloidosis Treatment Market Size study, by Treatment (Chemotherapy, Immunosuppressive Drugs, Transplantation, Supportive Care, Surgery), by End-use, and Regional Forecasts 2022-2032

<https://marketpublishers.com/r/G3969E926388EN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,218.00 (Single User License)

ID: G3969E926388EN

Abstracts

The Global Amyloidosis Treatment Market is valued at approximately USD 5.39 billion in 2023 and is anticipated to grow with a promising CAGR of more than 7.40% over the forecast period 2024–2032. Amyloidosis, a group of rare diseases characterized by the deposition of amyloid proteins in organs and tissues, has traditionally been underdiagnosed and underserved in clinical settings. However, recent medical advancements and diagnostic improvements have radically altered its trajectory. Innovative therapeutic approaches, including chemotherapy agents, immunosuppressive drugs, and stem cell transplantation, are being strategically deployed to improve survival rates and quality of life for patients suffering from different types of amyloidosis. As awareness grows and patient advocacy intensifies, stakeholders across the pharmaceutical industry are rapidly moving to bridge therapeutic gaps through cutting-edge solutions backed by molecular precision.

The increasing prevalence of chronic conditions such as multiple myeloma and kidney disease, both of which can precipitate secondary amyloidosis, is playing a pivotal role in driving market demand. Furthermore, medical research is unlocking novel biomarkers and genetic insights into hereditary amyloidosis, thereby accelerating the development of targeted therapies. Investments by biopharmaceutical giants and government health agencies into orphan disease R&D have also opened the floodgates for advanced pipeline drugs and monoclonal antibody therapies. However, the complexity of diagnosis, delayed treatment initiation, and limited awareness, especially in developing regions, continue to pose significant challenges. Moreover, the cost of therapies like autologous stem cell transplants can be prohibitive, further complicating accessibility for

a large patient population.

That said, emerging innovations are actively reshaping the treatment landscape. Ongoing clinical trials exploring RNA-interference therapies and fibril disaggregation agents demonstrate the shifting focus towards disease-modifying mechanisms rather than symptomatic management. In tandem, a broader adoption of personalized medicine frameworks is ensuring that treatment regimens are better tailored to individual patient profiles. As AI and machine learning integrate with diagnostic imaging and genetic sequencing tools, the ability to detect and stratify amyloidosis subtypes has grown significantly more efficient. These advancements are laying the foundation for a more proactive, evidence-based treatment ecosystem.

The digital health revolution and shift toward value-based care have also catalyzed a transformation in how amyloidosis is managed across clinical settings. Increasingly, healthcare systems are emphasizing early screening and long-term disease monitoring through real-world evidence and patient registries. This has prompted companies to roll out holistic care solutions that combine pharmacotherapy with telemedicine, patient education platforms, and data-driven follow-up care. Such models not only foster treatment adherence but also yield actionable insights that help refine therapeutic protocols across various stages of disease progression.

From a geographical standpoint, North America accounted for the largest share of the amyloidosis treatment market in 2023, attributed to its highly developed healthcare infrastructure, favorable reimbursement landscape, and active clinical trial ecosystem. Europe follows closely, driven by robust orphan drug legislations and high levels of public funding into rare disease research. Meanwhile, Asia Pacific is expected to register the fastest growth during the forecast period due to rising awareness, improving healthcare access, and increasing governmental initiatives supporting rare disease management. Latin America and the Middle East & Africa are also showing encouraging progress, largely propelled by growing urbanization and strategic healthcare collaborations with global NGOs and pharmaceutical firms.

Major market player included in this report are:

Takeda Pharmaceutical Company Limited

Pfizer Inc.

Johnson & Johnson Services, Inc.

Prothena Corporation plc

Teva Pharmaceutical Industries Ltd.

Celgene Corporation

GlaxoSmithKline plc

Janssen Biotech, Inc.

Amgen Inc.

Anylam Pharmaceuticals, Inc.

AbbVie Inc.

Alexion Pharmaceuticals, Inc.

Sanofi S.A.

Bristol-Myers Squibb Company

Regeneron Pharmaceuticals, Inc.

The detailed segments and sub-segment of the market are explained below:

By Treatment

Chemotherapy

Immunosuppressive Drugs

Transplantation

Supportive Care

Surgery

By End-use

Hospitals

Clinics

Academic & Research Institutes

Others

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Years considered for the study are as follows:

Historical Year – 2022

Base Year – 2023

Forecast Period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Contents

CHAPTER 1. GLOBAL AMYLOIDOSIS TREATMENT MARKET EXECUTIVE SUMMARY

- 1.1. Global Amyloidosis Treatment Market Size & Forecast (2022–2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
 - 1.3.1. By Treatment
 - 1.3.2. By End-use
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL AMYLOIDOSIS TREATMENT MARKET DEFINITION AND RESEARCH ASSUMPTIONS

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
 - 2.3.1. Inclusion & Exclusion
 - 2.3.2. Limitations
 - 2.3.3. Supply Side Analysis
 - 2.3.3.1. Availability
 - 2.3.3.2. Infrastructure
 - 2.3.3.3. Regulatory Environment
 - 2.3.3.4. Market Competition
 - 2.3.3.5. Economic Viability (Payer & Patient Perspectives)
 - 2.3.4. Demand Side Analysis
 - 2.3.4.1. Reimbursement Frameworks
 - 2.3.4.2. Diagnostic & Treatment Advancements
 - 2.3.4.3. Patient Awareness & Advocacy
 - 2.3.4.4. Healthcare Infrastructure
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
 - 2.5.1. Historical Year – 2022
 - 2.5.2. Base Year – 2023
 - 2.5.3. Forecast Period – 2024 to 2032
- 2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL AMYLOIDOSIS TREATMENT MARKET DYNAMICS

3.1. Market Drivers

- 3.1.1. Growing Incidence of Chronic Diseases Leading to Secondary Amyloidosis
- 3.1.2. Surge in Orphan Drug R&D Funding and Incentives
- 3.1.3. Advances in Targeted and Personalized Therapeutics

3.2. Market Challenges

- 3.2.1. Diagnostic Delays and Under-recognition of Disease Subtypes
- 3.2.2. High Cost and Accessibility Barriers for Advanced Therapies
- 3.2.3. Complex Regulatory Pathways for Novel Treatment Modalities

3.3. Market Opportunities

- 3.3.1. Emergence of RNA-Interference and Monoclonal Antibody Therapies
- 3.3.2. Integration of AI-Driven Diagnostic and Patient Monitoring Tools
- 3.3.3. Expansion into Emerging Markets with Growing Healthcare Spend

CHAPTER 4. GLOBAL AMYLOIDOSIS TREATMENT MARKET INDUSTRY ANALYSIS

4.1. Porter's 5 Force Model

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Forces
- 4.1.7. Impact Analysis of Porter's 5 Forces

4.2. PESTEL Analysis

- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

4.3. Top Investment Opportunity

4.4. Top Winning Strategies

4.5. Disruptive Trends

4.6. Industry Expert Perspective

4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE & FORECASTS BY TREATMENT 2022–2032

- 5.1. Segment Dashboard
- 5.2. Chemotherapy Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 5.3. Immunosuppressive Drugs Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 5.4. Transplantation Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 5.5. Supportive Care Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 5.6. Surgery Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

CHAPTER 6. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE & FORECASTS BY END-USE 2022–2032

- 6.1. Segment Dashboard
- 6.2. Hospitals Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 6.3. Clinics Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 6.4. Academic & Research Institutes Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 6.5. Others Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

CHAPTER 7. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE & FORECASTS BY REGION 2022–2032

- 7.1. North America Market
 - 7.1.1. U.S. Market
 - 7.1.2. Canada Market
- 7.2. Europe Market
 - 7.2.1. UK Market
 - 7.2.2. Germany Market
 - 7.2.3. France Market
 - 7.2.4. Spain Market
 - 7.2.5. Italy Market
 - 7.2.6. Rest of Europe Market
- 7.3. Asia Pacific Market
 - 7.3.1. China Market
 - 7.3.2. India Market
 - 7.3.3. Japan Market

- 7.3.4. Australia Market
- 7.3.5. South Korea Market
- 7.3.6. Rest of Asia Pacific Market
- 7.4. Latin America Market
 - 7.4.1. Brazil Market
 - 7.4.2. Mexico Market
 - 7.4.3. Rest of Latin America Market
- 7.5. Middle East & Africa Market
 - 7.5.1. Saudi Arabia Market
 - 7.5.2. South Africa Market
 - 7.5.3. Rest of Middle East & Africa Market

CHAPTER 8. COMPETITIVE INTELLIGENCE

- 8.1. Key Company SWOT Analysis
 - 8.1.1. Takeda Pharmaceutical Company Limited
 - 8.1.2. Pfizer Inc.
 - 8.1.3. Johnson & Johnson Services, Inc.
- 8.2. Top Market Strategies
- 8.3. Company Profiles
 - 8.3.1. Takeda Pharmaceutical Company Limited
 - 8.3.1.1. Key Information
 - 8.3.1.2. Overview
 - 8.3.1.3. Financial (Subject to Data Availability)
 - 8.3.1.4. Product Summary
 - 8.3.1.5. Market Strategies
 - 8.3.2. Pfizer Inc.
 - 8.3.3. Johnson & Johnson Services, Inc.
 - 8.3.4. Prothena Corporation plc
 - 8.3.5. Teva Pharmaceutical Industries Ltd.
 - 8.3.6. Celgene Corporation
 - 8.3.7. GlaxoSmithKline plc
 - 8.3.8. Janssen Biotech, Inc.
 - 8.3.9. Amgen Inc.
 - 8.3.10. Alnylam Pharmaceuticals, Inc.
 - 8.3.11. AbbVie Inc.
 - 8.3.12. Alexion Pharmaceuticals, Inc.
 - 8.3.13. Sanofi S.A.
 - 8.3.14. Bristol-Myers Squibb Company

8.3.15. Regeneron Pharmaceuticals, Inc.

CHAPTER 9. RESEARCH PROCESS

9.1. Research Process

9.1.1. Data Mining

9.1.2. Analysis

9.1.3. Market Estimation

9.1.4. Validation

9.1.5. Publishing

9.2. Research Attributes

I would like to order

Product name: Global Amyloidosis Treatment Market Size study, by Treatment (Chemotherapy, Immunosuppressive Drugs, Transplantation, Supportive Care, Surgery), by End-use, and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/G3969E926388EN.html>

Price: US\$ 3,218.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G3969E926388EN.html>